Next Article in Journal
Tetrandrine, a Compound Common in Chinese Traditional Medicine, Preferentially Kills Breast Cancer Tumor Initiating Cells (TICs) In Vitro
Next Article in Special Issue
Different Aspects of Self-Reported Quality of Life in 450 German Melanoma Survivors
Previous Article in Journal / Special Issue
Targeted Therapy for Biliary Tract Cancer
Article Menu

Export Article

Open AccessReview
Cancers 2011, 3(2), 2255-2273; doi:10.3390/cancers3022255

Targeted Therapy in Nonmelanoma Skin Cancers

Department of Dermatology, University of Rome “Tor Vergata”, Via Montpellier 1, 00199, Rome, Italy
Author to whom correspondence should be addressed.
Received: 11 March 2011 / Revised: 11 April 2011 / Accepted: 26 April 2011 / Published: 3 May 2011
(This article belongs to the Special Issue Cancer Diagnosis and Targeted Therapy)
View Full-Text   |   Download PDF [260 KB, uploaded 3 May 2011]   |  


Nonmelanoma skin cancer (NMSC) is the most prevalent cancer in light-skinned populations, and includes mainly Basal Cell Carcinomas (BCC), representing around 75% of NMSC and Squamous Cell Carcinomas (SCC). The incidence of these tumors is continuously growing. It was found that the overall number of procedures for NMSC in US rose by 76%, from 1,158,298 in 1992 to 2,048,517 in 2006. Although mortality from NMSC tends to be very low, clearly the morbidity related to these skin cancers is very high. Treatment options for NMSC include both surgical and nonsurgical interventions. Surgery was considered the gold standard therapy, however, advancements in the knowledge of pathogenic mechanisms of NMSCs led to the identification of key targets for drug intervention and to the consequent development of several targeted therapies. These represent the future in treatment of these common forms of cancer ensuring a high cure rate, preservation of the maximal amount of normal surrounding tissue and optimal cosmetic outcome. Here, we will review recent advancements in NMSC targeted therapies focusing on BCC and SCC.
Keywords: basal cell carcinoma (BCC); squamous cell carcinoma (SCC); EGFR; SMO inhibitor; COX2 basal cell carcinoma (BCC); squamous cell carcinoma (SCC); EGFR; SMO inhibitor; COX2
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Spallone, G.; Botti, E.; Costanzo, A. Targeted Therapy in Nonmelanoma Skin Cancers. Cancers 2011, 3, 2255-2273.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top